Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: anikatherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/17/2025 | $21.00 | Buy | B. Riley Securities |
| 11/1/2024 | $37.00 → $25.00 | Outperform | Barrington Research |
| 8/14/2023 | $24.00 | Mkt Perform → Outperform | Barrington Research |
| 3/7/2023 | Outperform → Mkt Perform | Barrington Research | |
| 11/9/2022 | $31.00 | Mkt Perform → Outperform | Barrington Research |
| 10/14/2022 | $26.00 | Equal-Weight | Stephens |
| 3/9/2022 | Outperform → Mkt Perform | Barrington Research | |
| 3/9/2022 | Overweight → Equal-Weight | Stephens & Co. | |
| 3/9/2022 | $35.00 | Overweight → Equal-Weight | Stephens |
| 11/16/2021 | $55.00 | Overweight | Stephens & Co. |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Anika Therapeutics, Inc. (0000898437) (Issuer)
4 - Anika Therapeutics, Inc. (0000898437) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
B. Riley Securities initiated coverage of Anika Therapeutics with a rating of Buy and set a new price target of $21.00
Barrington Research reiterated coverage of Anika Therapeutics with a rating of Outperform and set a new price target of $25.00 from $37.00 previously
Barrington Research upgraded Anika Therapeutics from Mkt Perform to Outperform and set a new price target of $24.00
Barrington Research downgraded Anika Therapeutics from Outperform to Mkt Perform
Barrington Research upgraded Anika Therapeutics from Mkt Perform to Outperform and set a new price target of $31.00
Stephens resumed coverage of Anika Therapeutics with a rating of Equal-Weight and set a new price target of $26.00
Barrington Research downgraded Anika Therapeutics from Outperform to Mkt Perform
Stephens & Co. downgraded Anika Therapeutics from Overweight to Equal-Weight
Stephens downgraded Anika Therapeutics from Overweight to Equal-Weight and set a new price target of $35.00
Stephens & Co. initiated coverage of Anika Therapeutics with a rating of Overweight and set a new price target of $55.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Anika Therapeutics, Inc. (0000898437) (Issuer)
4 - Anika Therapeutics, Inc. (0000898437) (Issuer)
4 - Anika Therapeutics, Inc. (0000898437) (Issuer)
4 - Anika Therapeutics, Inc. (0000898437) (Issuer)
4 - Anika Therapeutics, Inc. (0000898437) (Issuer)
4 - Anika Therapeutics, Inc. (0000898437) (Issuer)
4 - Anika Therapeutics, Inc. (0000898437) (Issuer)
4 - Anika Therapeutics, Inc. (0000898437) (Issuer)
4 - Anika Therapeutics, Inc. (0000898437) (Issuer)
4 - Anika Therapeutics, Inc. (0000898437) (Issuer)
DEFA14A - Anika Therapeutics, Inc. (0000898437) (Filer)
10-Q - Anika Therapeutics, Inc. (0000898437) (Filer)
8-K - Anika Therapeutics, Inc. (0000898437) (Filer)
DEFA14A - Anika Therapeutics, Inc. (0000898437) (Filer)
DEF 14A - Anika Therapeutics, Inc. (0000898437) (Filer)
SCHEDULE 13G/A - Anika Therapeutics, Inc. (0000898437) (Subject)
8-K - Anika Therapeutics, Inc. (0000898437) (Filer)
8-K - Anika Therapeutics, Inc. (0000898437) (Filer)
SCHEDULE 13G/A - Anika Therapeutics, Inc. (0000898437) (Subject)
S-8 - Anika Therapeutics, Inc. (0000898437) (Filer)
Fastest customizable press release news feed in the world
MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company's next phase of commercial growth and operational excellence. In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company's 2026 Annual Meeting of Stockholders on June 9, 2026 (the "2026 Annual Meeting"), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial strategy,
Grew total company revenue 13%, driven by Commercial Channel strength and favorable OEM Channel order timing Delivered 64% gross margin, +8 points year over year, driven by improved operational execution Operational transformation generating early wins, delivering $4 million of adjusted EBITDA BEDFORD, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early‑intervention orthopedics, today announced financial results for the first quarter of 2026. Total revenue for the first quarter of 2026 was $29.6 million, compared to $26.2 million in the prior-ye
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Cheryl R. Blanchard, Ph.D. to the company's board of directors. The company also announced that Christina Rossi has stepped down from its board of directors, effective April 15, 2026. "Cheryl brings over three decades of leadership experience advancing the development of innovative products across biologics, small molecules and medical devices, and I am pleased to welcome her to the board," said Sara Bonstein, chair of the board of direct
BEDFORD, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2026 financial results before the opening of the market on Wednesday, April 29, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 82141. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.an
MELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces two additional Non-Executive Director (NED) appointments, effective May 11, 20261, as part of Board expansion and succession planning: Maria Rivas, MD is an experienced public company board director and S&P 100 senior pharmaceutical executive with more than 25 years' experience in late-stage clinical development, commercialization and governance leadership. Dr. Rivas currently serves on the board of directors of The Cooper Companies, Inc. (NASDAQ:COO), a medical technology company, and also served as an independent director for Medidata
BEDFORD, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on April 1, 2026, Anika granted restricted stock units ("RSUs") covering an aggregate of 3,138 shares of common stock to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made a
Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 million operating cash flow and $4.4 million in free cash flow for the full year FDA response for Hyalofast® PMA received in January 2026, Anika developing responses for submission BEDFORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early‑intervention orthopedics, today announced financial results for the fourth quarter and full year ended December 3
BEDFORD, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that Steve Griffin, President and CEO of Anika, will present at the Canaccord Genuity 2026 Musculoskeletal Conference in New Orleans on Monday, March 2, 2026 at 11:30am CT / 12:30pm ET. Management will also participate in one-on-one investor meetings throughout the event. The presentation will be webcast live on the Events and Webcasts page under the Investors section of Anika Therapeutics' website and will be archived for 30 days following the presentation. For more information about this event or to schedule a on
BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2025 financial results before the opening of the market on Thursday, February 26, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 89327. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's
NEWTON, Mass., Feb. 4, 2026 /PRNewswire/ -- Lumicell, Inc., a leader in developing innovative fluorescence-guided imaging technologies for cancer detection, today announced the appointment of Cheryl R. Blanchard, Ph.D., to its Board of Directors. Dr. Blanchard is an accomplished biotech and medtech CEO and board member with more than 30 years of experience building, scaling, and transforming public and private life sciences companies. Dr. Blanchard most recently served as President, CEO, and Director of Anika Therapeutics (NASDAQ:ANIK), where she led the successful implementat
Live finance-specific insights
Grew total company revenue 13%, driven by Commercial Channel strength and favorable OEM Channel order timing Delivered 64% gross margin, +8 points year over year, driven by improved operational execution Operational transformation generating early wins, delivering $4 million of adjusted EBITDA BEDFORD, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early‑intervention orthopedics, today announced financial results for the first quarter of 2026. Total revenue for the first quarter of 2026 was $29.6 million, compared to $26.2 million in the prior-ye
BEDFORD, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2026 financial results before the opening of the market on Wednesday, April 29, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 82141. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.an
Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 million operating cash flow and $4.4 million in free cash flow for the full year FDA response for Hyalofast® PMA received in January 2026, Anika developing responses for submission BEDFORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early‑intervention orthopedics, today announced financial results for the fourth quarter and full year ended December 3
BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2025 financial results before the opening of the market on Thursday, February 26, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 89327. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's
Commercial Channel revenue up 22% with continued strong Integrity™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth Third and final Hyalofast PMA module filed and data released Cingal® achieved commercial milestone of more than one million injections worldwide since 2016 Reaffirming Fiscal 2025 guidance and long-term outlook and commencing a $15 million 10b5-1 share repurchase BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced financial results for th
BEDFORD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2025 financial results before the opening of the market on Wednesday, November 5, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 53754. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.a
Regenerative Solutions revenue up 41% with Integrity™ Implant System ahead of expectations and continued strong Hyalofast® growth; Integrity surpasses full year 2024 performance and is on pace to more than double in 2025 Company released topline results for Hyalofast® clinical trial which did not meet pre-specified co-primary end points; Hyalofast demonstrated statistically significant improvements in pre-defined secondary endpoints and other measures; Company plans to file the final PMA module in second half 2025 Reaffirming Fiscal 2025 Revenue and EBITDA guidance; revising long-term outlook to reflect potential timing of FDA review for Hyalofast launch BEDFORD, Mass., July
BEDFORD, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its second quarter 2025 financial results before the opening of the market on Wednesday, July 30, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 48251. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.ani
First Quarter 2025 Commercial Channel revenue up 18% Integrity™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Updating Fiscal 2025 OEM Channel revenue guidance and Adjusted EBITDA guidance BEDFORD, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 ResultsAnika announced first quarter reven
BEDFORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2025 financial results before the opening of the market on Friday, May 9, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 63463. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.anika.co
Live Leadership Updates
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Cheryl R. Blanchard, Ph.D. to the company's board of directors. The company also announced that Christina Rossi has stepped down from its board of directors, effective April 15, 2026. "Cheryl brings over three decades of leadership experience advancing the development of innovative products across biologics, small molecules and medical devices, and I am pleased to welcome her to the board," said Sara Bonstein, chair of the board of direct
NEWTON, Mass., Feb. 4, 2026 /PRNewswire/ -- Lumicell, Inc., a leader in developing innovative fluorescence-guided imaging technologies for cancer detection, today announced the appointment of Cheryl R. Blanchard, Ph.D., to its Board of Directors. Dr. Blanchard is an accomplished biotech and medtech CEO and board member with more than 30 years of experience building, scaling, and transforming public and private life sciences companies. Dr. Blanchard most recently served as President, CEO, and Director of Anika Therapeutics (NASDAQ:ANIK), where she led the successful implementat
Stephen (Steve) Griffin, Current Chief Financial Officer and Chief Operating Officer, Appointed President and Chief Executive OfficerCheryl Blanchard to Become Executive Chair of the Board of Directors BEDFORD, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that Stephen (Steve) Griffin, current Executive Vice President, Chief Financial Officer and Chief Operating Officer, has been appointed President and Chief Executive Officer and a member of the Board of Directors, effective February 1, 2026. Mr. Griff
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
Appoints Joseph Capper and William Jellison to Board of DirectorsAnnounces New $40 Million Share Repurchase Program BEDFORD, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has entered into a cooperation agreement with Caligan Partners LP ("Caligan"). As part of the agreement, Joseph Capper, CEO of MIMEDX, and William Jellison, former CFO of Stryker, have been appointed to the Company's Board of Directors, effective immediately. Messrs. Capper and Jellison have nearly 50 years of combined experience building value and driving transformative growth at MedTech compa
BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has appointed Steve Griffin as the Company's Executive Vice President, Chief Financial Officer ("CFO") and Treasurer, effective June 3, 2024. He succeeds Michael Levitz, who has decided to step down as CFO after almost four years with the company. Mr. Levitz will remain with the Company through December 31, 2024, to ensure a smooth transition. "We are pleased to welcome Steve to Anika as we focus on accelerating our pivot to profitability," said Cheryl Blanchard, Ph.D., Anika's President and CEO. "Steve
BEDFORD, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that its Board of Directors has appointed Sheryl Conley as independent director, effective October 28, 2021. Sheryl Conley joins the Anika Board of Directors with over 35 years of orthopedic and healthcare industry experience, most recently as President and CEO of OrthoWorx, Inc., and previously as Group President, Americas and Global Brand Management, and Chief Marketing Officer for Zimmer, Inc. Ms. Conley brings extensive orthopedic medical device industry knowledge with a focus on global brand management
This live feed shows all institutional transactions in real time.
SC 13G/A - Anika Therapeutics, Inc. (0000898437) (Subject)
SC 13D/A - Anika Therapeutics, Inc. (0000898437) (Subject)
SC 13D/A - Anika Therapeutics, Inc. (0000898437) (Subject)
SC 13G/A - Anika Therapeutics, Inc. (0000898437) (Subject)
SC 13G/A - Anika Therapeutics, Inc. (0000898437) (Subject)
SC 13G/A - Anika Therapeutics, Inc. (0000898437) (Subject)
SC 13G/A - Anika Therapeutics, Inc. (0000898437) (Subject)
SC 13D/A - Anika Therapeutics, Inc. (0000898437) (Subject)
SC 13D - Anika Therapeutics, Inc. (0000898437) (Subject)
SC 13G/A - Anika Therapeutics, Inc. (0000898437) (Subject)